PL2838516T3 - Zapobiegające nadużywaniu kompozycje farmaceutyczne o natychmiastowym uwalnianiu - Google Patents

Zapobiegające nadużywaniu kompozycje farmaceutyczne o natychmiastowym uwalnianiu

Info

Publication number
PL2838516T3
PL2838516T3 PL13719672T PL13719672T PL2838516T3 PL 2838516 T3 PL2838516 T3 PL 2838516T3 PL 13719672 T PL13719672 T PL 13719672T PL 13719672 T PL13719672 T PL 13719672T PL 2838516 T3 PL2838516 T3 PL 2838516T3
Authority
PL
Poland
Prior art keywords
pharmaceutical compositions
immediate release
abuse deterrent
deterrent pharmaceutical
abuse
Prior art date
Application number
PL13719672T
Other languages
English (en)
Inventor
Siva N. Raman
Jae Han Park
Thomas A. Diezi
Clifford J. Herman
Sunil K. Battu
Eric A. Burge
Original Assignee
SpecGx LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SpecGx LLC filed Critical SpecGx LLC
Publication of PL2838516T3 publication Critical patent/PL2838516T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL13719672T 2012-04-18 2013-04-18 Zapobiegające nadużywaniu kompozycje farmaceutyczne o natychmiastowym uwalnianiu PL2838516T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261625926P 2012-04-18 2012-04-18
US201361792478P 2013-03-15 2013-03-15
EP13719672.1A EP2838516B1 (en) 2012-04-18 2013-04-18 Immediate release, abuse deterrent pharmaceutical compositions
PCT/US2013/037056 WO2013158814A1 (en) 2012-04-18 2013-04-18 Immediate release, abuse deterrent pharmaceutical compositions

Publications (1)

Publication Number Publication Date
PL2838516T3 true PL2838516T3 (pl) 2019-05-31

Family

ID=48227563

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13719672T PL2838516T3 (pl) 2012-04-18 2013-04-18 Zapobiegające nadużywaniu kompozycje farmaceutyczne o natychmiastowym uwalnianiu

Country Status (10)

Country Link
US (4) US9993422B2 (pl)
EP (1) EP2838516B1 (pl)
JP (1) JP6067100B2 (pl)
BR (1) BR112014024382B1 (pl)
CA (1) CA2864738C (pl)
ES (1) ES2699806T3 (pl)
IL (1) IL234997B (pl)
MX (1) MX356111B (pl)
PL (1) PL2838516T3 (pl)
WO (1) WO2013158814A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
MX363844B (es) 2013-03-15 2019-04-05 SpecGx LLC Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional.
WO2015023675A2 (en) * 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9770514B2 (en) 2013-09-03 2017-09-26 ExxPharma Therapeutics LLC Tamper-resistant pharmaceutical dosage forms
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3164117B1 (en) * 2014-07-03 2023-09-06 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides
DK3169315T3 (da) * 2014-07-17 2020-08-10 Pharmaceutical Manufacturing Res Services In Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2016199170A2 (en) * 2015-06-10 2016-12-15 Cipla Limited Paliperidone palmitate particles and compositions thereof
US9943513B1 (en) 2015-10-07 2018-04-17 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
US11065246B2 (en) 2016-02-08 2021-07-20 SpecGx LLC Glucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
CN110035740B (zh) 2016-11-02 2023-08-04 中枢疗法公司 稳定的水性辣椒素可注射制剂及其医学用途
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
BR112020000989A2 (pt) 2017-07-20 2020-07-14 Centrexion Therapeutics Corporation métodos e composições para tratamento de dor com o uso de capsaicina
EP3473246A1 (en) 2017-10-19 2019-04-24 Capsugel Belgium NV Immediate release abuse deterrent formulations
WO2020068510A1 (en) 2018-09-25 2020-04-02 SpecGx LLC Abuse deterrent immediate release capsule dosage forms
CN114555031A (zh) * 2019-08-27 2022-05-27 应用材料公司 用于药物防滥用制剂的气相包衣技术
KR102603701B1 (ko) * 2020-12-04 2023-11-17 한국생산기술연구원 팽창성 창상피복재 및 이의 제조방법

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2211485A (en) * 1940-08-13 Effervescent acetyl salicylic acid
JPS537495B2 (pl) 1973-05-21 1978-03-18
US3980766A (en) 1973-08-13 1976-09-14 West Laboratories, Inc. Orally administered drug composition for therapy in the treatment of narcotic drug addiction
DE2530563C2 (de) 1975-07-09 1986-07-24 Bayer Ag, 5090 Leverkusen Analgetische Arzneimittel mit vermindertem Mißbrauchspotential
US4678661A (en) 1983-09-28 1987-07-07 Gerhard Gergely Effervescent composition and method of making same
JPH0747532B2 (ja) 1985-10-16 1995-05-24 花王株式会社 錠剤の製造方法
US4956182A (en) 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
GB9401894D0 (en) 1994-02-01 1994-03-30 Rhone Poulenc Rorer Ltd New compositions of matter
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
JP5026635B2 (ja) 1998-09-10 2012-09-12 ニュコメデ ダンマルク アンパーツセルスカブ 医薬物質の迅速放出医薬組成物
US20080102121A1 (en) 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US6340471B1 (en) 1999-12-30 2002-01-22 Alvin Kershman Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6541025B1 (en) 1999-12-30 2003-04-01 Shear/Kershman Laboratories, Inc. Method for preparing solid delivery system for encapsulated and non-encapsulated pharmaceuticals
US6660302B1 (en) 2000-09-06 2003-12-09 Chr. Hansen, Inc. Dry-powder film coating composition and method of preparation
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20080050422A1 (en) * 2001-10-12 2008-02-28 Monosolrx, Llc. Method of administering a film product containing a drug
WO2003032954A1 (en) 2001-10-17 2003-04-24 Dr. Reddy's Laboratories Ltd. Stabilized pharmaceutical formulations containing amlodipine maleate
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20040005359A1 (en) 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004020220A1 (de) 2004-04-22 2005-11-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
EP1658054B1 (de) 2003-08-06 2007-06-27 Grünenthal GmbH Gegen missbrauch gesicherte darreichungsform
US7658944B2 (en) 2003-10-10 2010-02-09 Lifecycle Pharma A/S Solid dosage form comprising a fibrate
US20050245557A1 (en) 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
AU2013206525B2 (en) 2003-11-26 2015-09-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
US20050165038A1 (en) 2004-01-22 2005-07-28 Maxwell Gordon Analgetic dosage forms that are resistant to parenteral and inhalation dosing and have reduced side effects
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US8093408B2 (en) 2005-06-21 2012-01-10 The Company Wockhardt Antidepressant oral pharmaceutical compositions
US20070020186A1 (en) 2005-07-22 2007-01-25 Alpex Pharma S.A. Solid dosage formulations of narcotic drugs having improved buccal adsorption
PL116330U1 (en) 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
US8329744B2 (en) 2005-11-02 2012-12-11 Relmada Therapeutics, Inc. Methods of preventing the serotonin syndrome and compositions for use thereof
US8652529B2 (en) 2005-11-10 2014-02-18 Flamel Technologies Anti-misuse microparticulate oral pharmaceutical form
US20090317355A1 (en) 2006-01-21 2009-12-24 Abbott Gmbh & Co. Kg, Abuse resistant melt extruded formulation having reduced alcohol interaction
WO2007109104A2 (en) 2006-03-16 2007-09-27 Tris Pharma, Inc. Modified release formulations containing drug-ion exchange resin complexes
US8173152B2 (en) 2006-03-24 2012-05-08 Auxilium Us Holdings, Llc Stabilized compositions containing alkaline labile drugs
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
ES2300188B1 (es) 2006-05-24 2009-05-01 Ferrer Internacional, S.A. Comprimido bicapa para la prevencion de los accidentes cardiovasculares.
US20080069891A1 (en) 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
US20080075771A1 (en) 2006-07-21 2008-03-27 Vaughn Jason M Hydrophilic opioid abuse deterrent delivery system using opioid antagonists
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
WO2008086804A2 (en) 2007-01-16 2008-07-24 Egalet A/S Use of i) a polyglycol and n) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
US9326979B2 (en) 2007-03-02 2016-05-03 Teika Pharmaceutical Co., Ltd. Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
KR101506607B1 (ko) * 2007-04-13 2015-03-30 켐제닉스 파마슈티칼스 인크. 세팔로탁신 경구 제형
US9125836B2 (en) * 2007-06-07 2015-09-08 Sato Pharmaceutical Co., Ltd. Film preparation with rapidly dissolving property and flexibility
US20090124650A1 (en) 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
JP5965583B2 (ja) 2007-08-13 2016-08-10 インスピリオン デリバリー テクノロジーズ エルエルシー 乱用抵抗性医薬組成物、その使用方法および作製方法
DK2200588T3 (da) 2007-09-25 2019-07-01 Solubest Ltd Sammensætninger, som omfatter lipofile aktive forbindelser, og fremgangsmåde til fremstilling deraf
JP5651818B2 (ja) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド 誤用を防止するための放出制御製剤
NZ586792A (en) 2008-01-25 2012-09-28 Gruenenthal Chemie Tamper resistant controlled release pharmaceutical tablets form having convex and concave surfaces
US8729070B2 (en) 2008-02-20 2014-05-20 Targia Pharmaceuticals CNS pharmaceutical compositions and methods of use
WO2009136625A1 (ja) 2008-05-07 2009-11-12 大日本住友製薬株式会社 環状アミン－１－カルボン酸エステル誘導体およびそれを含有する医薬組成物
CN102159193B (zh) 2008-09-18 2015-09-16 普渡制药公司 包含聚(ε-己内酯)的药物剂型
WO2010035273A2 (en) 2008-09-29 2010-04-01 Intec Pharma Ltd. Novel gastroretentive delivery system
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
ES2718688T3 (es) 2009-07-22 2019-07-03 Gruenenthal Gmbh Forma de dosificación resistente a la manipulación para opioides sensibles a la oxidación
JP5017516B2 (ja) 2009-11-13 2012-09-05 株式会社ホットアルバム炭酸泉タブレット 錠剤の製造方法
WO2011066980A2 (en) 2009-12-04 2011-06-09 Lars Holger Hermann Oral dosage forms with reduced potential for drug abuse
WO2011079074A1 (en) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20120321674A1 (en) 2011-02-17 2012-12-20 Michael Vachon Technology for Preventing Abuse of Solid Dosage Forms
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
BR112013021026A2 (pt) 2011-02-17 2016-10-11 Qrxpharma Ltd tecnologia para prevenção de abuso de formas de dosagem sólidas
CA2853764C (en) 2011-11-22 2017-05-16 Watson Pharmaceuticals, Inc. Immediate release abuse deterrent tablet
WO2013158810A1 (en) 2012-04-18 2013-10-24 Mallinckrodt Llc Immediate release pharmaceutical compositions with abuse deterrent properties
ES2699806T3 (es) 2012-04-18 2019-02-12 SpecGx LLC Composiciones farmacéuticas, disuasivas del abuso, de liberación inmediata
WO2014011830A1 (en) 2012-07-12 2014-01-16 Mallinckrodt Llc Extended release, abuse deterrent pharmaceutical compositions
MX363844B (es) 2013-03-15 2019-04-05 SpecGx LLC Forma de dosificación sólida de disuasivo del abuso para liberación inmediata con marca funcional.
EP3164117B1 (en) 2014-07-03 2023-09-06 SpecGx LLC Abuse deterrent immediate release formulations comprising non-cellulose polysaccharides

Also Published As

Publication number Publication date
BR112014024382A2 (pl) 2017-06-20
JP6067100B2 (ja) 2017-01-25
US20180256493A1 (en) 2018-09-13
EP2838516A1 (en) 2015-02-25
US20180008532A1 (en) 2018-01-11
WO2013158814A8 (en) 2014-06-19
CA2864738C (en) 2017-07-18
ES2699806T3 (es) 2019-02-12
EP2838516B1 (en) 2018-10-17
US20130280177A1 (en) 2013-10-24
MX2014009876A (es) 2014-11-13
CA2864738A1 (en) 2013-10-24
US9993422B2 (en) 2018-06-12
BR112014024382B1 (pt) 2022-08-09
JP2015514775A (ja) 2015-05-21
IL234997B (en) 2019-02-28
WO2013158814A1 (en) 2013-10-24
US20180280289A1 (en) 2018-10-04
MX356111B (es) 2018-05-15

Similar Documents

Publication Publication Date Title
IL234997B (en) Immediate release pharmaceutical preparations designed to prevent abuse
HK1210599A1 (en) Abuse deterrent pharmaceutical compositions for controlled release
IL236648A0 (en) Delayed release abuse prevention pharmaceuticals
IL234996A0 (en) Hand-release pharmacy preparations with properties to prevent abuse
HK1209638A1 (en) Pharmaceutical compositions
ZA201501930B (en) Pharmaceutical composition
EP2782558A4 (en) MISSABLE TABLET WITH IMMEDIATE RELEASE
EP2832730A4 (en) MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
IL233824A (en) Compounds 1h - Indazole - 3 - Carboxamide, preparations containing them and their use
EP2903979A4 (en) Novel compounds, their preparation and use
HK1209047A1 (en) Novel pharmaceutical composition
IL280316B (en) Amphiphilic compounds, preparations and their use
IL237542B (en) Amphiphilic compounds, their preparations and uses
GB201300064D0 (en) Microparticle compositions
ZA201502987B (en) Pharmaceutical composition
IL237540A0 (en) Amphiphilic compounds, their preparations and uses
IL237538B (en) Amphiphilic compounds, their preparations and uses
EP2897590A4 (en) PHARMACEUTICAL COMPOSITION
GB201211153D0 (en) Pharmaceutical compositions
IL237539A0 (en) Amphiphilic compounds, their preparations and uses
EP2851078A4 (en) PHARMACEUTICAL COMPOSITION
IL238075A0 (en) pharmaceutical preparations
ZA201400751B (en) Pharmaceutical composition
GB201219234D0 (en) Pharmaceutical compositions
GB201213303D0 (en) Pharmaceutical compositions